Herpes simplex viruses (HSV) type 1 and 2 cause lifelong latent infections that can lead to recurrent painful blisters. HSV-1 is common (infecting 40-60% of people) and predominantly induces lip, mouth and facial blisters, or the genitalia. HSV-2 is more usually sexually transmitted and affects the genitalia in about 20% of the population, but can also infect the oral mucosa.
Although therapeutic drugs are available, their efficacy is limited and there is not currently a vaccine against these viruses.
Mymetics' HSV vaccine approach
Mymetics is developing a preventive HSV-1 and -2 vaccine, consisting of a virosome, which is the natural herpes virus envelope containing most of the natural membrane proteins and a possibility to include an adjuvant.
Latest Results and Next Steps
Exploratory experiments were performed on mice in which the immunogenicity of HSV-1 virosomes were investigated, following injections through various routes (intra-muscular and intra-nasal) neutralizing antibodies were generated.
Mymetics is currently evaluating the next stages for this promising vaccine candidate.